[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on BMY. Bristol-Myers Squibb Company (BMY)’s share was trading at $59.01 as of March 16th. BMY’s trailing and forward P/E were 22.79 and 8.73 respectively according to Yahoo Finance. Bristol-Myers Squibb (BMY) […]",
    "url": "https://finnhub.io/api/news?id=5a9fdb38be9c1cc6d106f9aa8989832202178e59213e8698e3a9b876d6021175",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742232900,
      "headline": "Bristol-Myers Squibb Company (BMY): A Bull Case Theory",
      "id": 133325486,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on BMY. Bristol-Myers Squibb Company (BMY)’s share was trading at $59.01 as of March 16th. BMY’s trailing and forward P/E were 22.79 and 8.73 respectively according to Yahoo Finance. Bristol-Myers Squibb (BMY) […]",
      "url": "https://finnhub.io/api/news?id=5a9fdb38be9c1cc6d106f9aa8989832202178e59213e8698e3a9b876d6021175"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=463917d8e8c531245b579c399efe18768361183c6939ff2276cb33bcebf2f3bd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742229420,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 133220595,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=463917d8e8c531245b579c399efe18768361183c6939ff2276cb33bcebf2f3bd"
    }
  },
  {
    "ts": null,
    "headline": "EC approves Bristol Myers Squibb’s follicular lymphoma CAR T therapy",
    "summary": "The approval is supported by outcomes from the multicentre, open-label Phase II TRANSCEND FL trial.",
    "url": "https://finnhub.io/api/news?id=c3564d09e2df6471b1edfe3addd07d9ab4acfa6e20a396d8685e7fdc55a9630f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742203332,
      "headline": "EC approves Bristol Myers Squibb’s follicular lymphoma CAR T therapy",
      "id": 133325487,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The approval is supported by outcomes from the multicentre, open-label Phase II TRANSCEND FL trial.",
      "url": "https://finnhub.io/api/news?id=c3564d09e2df6471b1edfe3addd07d9ab4acfa6e20a396d8685e7fdc55a9630f"
    }
  }
]